GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RBC Bioscience Corp (ROCO:6848) » Definitions » Asset Turnover

RBC Bioscience (ROCO:6848) Asset Turnover : 0.11 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is RBC Bioscience Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. RBC Bioscience's Revenue for the six months ended in Dec. 2023 was NT$83.5 Mil. RBC Bioscience's Total Assets for the quarter that ended in Dec. 2023 was NT$758.5 Mil. Therefore, RBC Bioscience's Asset Turnover for the quarter that ended in Dec. 2023 was 0.11.

Asset Turnover is linked to ROE % through Du Pont Formula. RBC Bioscience's annualized ROE % for the quarter that ended in Dec. 2023 was 3.46%. It is also linked to ROA % through Du Pont Formula. RBC Bioscience's annualized ROA % for the quarter that ended in Dec. 2023 was 1.09%.


RBC Bioscience Asset Turnover Historical Data

The historical data trend for RBC Bioscience's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RBC Bioscience Asset Turnover Chart

RBC Bioscience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial 0.88 1.61 0.37 0.21 0.22

RBC Bioscience Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.12 0.09 0.11 0.11

Competitive Comparison of RBC Bioscience's Asset Turnover

For the Biotechnology subindustry, RBC Bioscience's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RBC Bioscience's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RBC Bioscience's Asset Turnover distribution charts can be found below:

* The bar in red indicates where RBC Bioscience's Asset Turnover falls into.



RBC Bioscience Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

RBC Bioscience's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=172.467/( (790.546+753.79)/ 2 )
=172.467/772.168
=0.22

RBC Bioscience's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=83.527/( (763.194+753.79)/ 2 )
=83.527/758.492
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


RBC Bioscience  (ROCO:6848) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

RBC Bioscience's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=8.248/238.647
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(8.248 / 167.054)*(167.054 / 758.492)*(758.492/ 238.647)
=Net Margin %*Asset Turnover*Equity Multiplier
=4.94 %*0.2202*3.1783
=ROA %*Equity Multiplier
=1.09 %*3.1783
=3.46 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

RBC Bioscience's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=8.248/758.492
=(Net Income / Revenue)*(Revenue / Total Assets)
=(8.248 / 167.054)*(167.054 / 758.492)
=Net Margin %*Asset Turnover
=4.94 %*0.2202
=1.09 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


RBC Bioscience Asset Turnover Related Terms

Thank you for viewing the detailed overview of RBC Bioscience's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


RBC Bioscience (ROCO:6848) Business Description

Traded in Other Exchanges
N/A
Address
Lane 235, Baoqiao Road, 3rd Floor, No. 132, New Taipei City, TWN, 23145
RBC Bioscience Corp is a bio sciences company. Its products include Real Genomics, MagCore Automated Nucleic Acid Extractor, and MagCore Nucleic Acid Extraction KIT.

RBC Bioscience (ROCO:6848) Headlines

No Headlines